Physician profile
Gerardo Dumapit
NPI 1619929627
$8,897.51
in general payments reported to CMS, 2019-2025
28 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,098 · 2020: $2,372 · 2021: $1,837 · 2022: $1,042 · 2023: $575 · 2024: $578 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,548 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,548.16 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,334.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $861.74 | 2019-2023 | |
| Amarin Pharma, INC. | $775.31 | 2019-2022 | |
| Pfizer INC. | $701.50 | 2019-2025 | |
| Horizon Therapeutics Plc | $697.07 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $611.01 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Kowa Pharmaceuticals America, INC. | $370.53 | 2019-2025 | Zoryve |
| Lilly USA, LLC | $346.23 | 2019-2025 | Jardiance, Mounjaro, Lyumjev |
| Leo Pharma INC. | $344.05 | 2019-2021 | |
| Astellas Pharma US INC | $334.10 | 2020-2022 | |
| Exact Sciences Corporation | $316.93 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $295.88 | 2019-2020 | |
| Abbvie INC. | $156.94 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $134.79 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.14 | 2019-2025 | Xifaxan |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $96.21 | 2021-2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $66.24 | 2022-2024 | |
| Esperion Therapeutics, INC. | $51.01 | 2021-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.15 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $42.57 | 2023-2024 | Jynarque |
| Abbott Laboratories | $39.81 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $39.43 | 2021-2023 | |
| Althera Pharmaceuticals LLC | $26.44 | 2021 | |
| Genentech USA, INC. | $26.26 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.76 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.79 | 2025 | Eliquis |
| Dexcom, INC. | $11.30 | 2021 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Dumapit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.